Product development partnerships hit their stride: Lessons from developing a meningitis vaccine for Africa

David M Bishai, Claire Champion, Michael E. Steele, Lindsay Thompson

Research output: Contribution to journalArticle

Abstract

The Meningitis Vaccine Project, a so-called product development partnership, developed a new vaccine against bacterial meningitis, an inflammation of brain tissues that causes an estimated 10,000 deaths among African children and young people each year. The vaccine-known as MenAfriVac and specifically targeted for use in lowincome countries in Africa-was designed to be made available to governments at a price of fifty cents per dose. The Meningitis Vaccine Project is an example of how product development partnerships have reinvigorated research on vaccines for neglected diseases. These partnerships disperse the multiple tasks of product development across a network of partners that are best suited for each task. The vaccine was rapidly embraced by African health officials, and in its first few weeks on the market, in late 2010, more than nineteen million people in Burkina Faso, Mali, and Niger were vaccinated.

Original languageEnglish (US)
Pages (from-to)1058-1064
Number of pages7
JournalHealth Affairs
Volume30
Issue number6
DOIs
StatePublished - Jun 2011

Fingerprint

Meningitis
Vaccines
Neglected Diseases
Mali
Burkina Faso
Niger
Bacterial Meningitides
Encephalitis
Health
Research

ASJC Scopus subject areas

  • Health Policy

Cite this

Product development partnerships hit their stride : Lessons from developing a meningitis vaccine for Africa. / Bishai, David M; Champion, Claire; Steele, Michael E.; Thompson, Lindsay.

In: Health Affairs, Vol. 30, No. 6, 06.2011, p. 1058-1064.

Research output: Contribution to journalArticle

Bishai, David M ; Champion, Claire ; Steele, Michael E. ; Thompson, Lindsay. / Product development partnerships hit their stride : Lessons from developing a meningitis vaccine for Africa. In: Health Affairs. 2011 ; Vol. 30, No. 6. pp. 1058-1064.
@article{a708888820f9436c93d9f04e203f0f3e,
title = "Product development partnerships hit their stride: Lessons from developing a meningitis vaccine for Africa",
abstract = "The Meningitis Vaccine Project, a so-called product development partnership, developed a new vaccine against bacterial meningitis, an inflammation of brain tissues that causes an estimated 10,000 deaths among African children and young people each year. The vaccine-known as MenAfriVac and specifically targeted for use in lowincome countries in Africa-was designed to be made available to governments at a price of fifty cents per dose. The Meningitis Vaccine Project is an example of how product development partnerships have reinvigorated research on vaccines for neglected diseases. These partnerships disperse the multiple tasks of product development across a network of partners that are best suited for each task. The vaccine was rapidly embraced by African health officials, and in its first few weeks on the market, in late 2010, more than nineteen million people in Burkina Faso, Mali, and Niger were vaccinated.",
author = "Bishai, {David M} and Claire Champion and Steele, {Michael E.} and Lindsay Thompson",
year = "2011",
month = "6",
doi = "10.1377/hlthaff.2011.0295",
language = "English (US)",
volume = "30",
pages = "1058--1064",
journal = "Health Affairs",
issn = "0278-2715",
publisher = "Project Hope",
number = "6",

}

TY - JOUR

T1 - Product development partnerships hit their stride

T2 - Lessons from developing a meningitis vaccine for Africa

AU - Bishai, David M

AU - Champion, Claire

AU - Steele, Michael E.

AU - Thompson, Lindsay

PY - 2011/6

Y1 - 2011/6

N2 - The Meningitis Vaccine Project, a so-called product development partnership, developed a new vaccine against bacterial meningitis, an inflammation of brain tissues that causes an estimated 10,000 deaths among African children and young people each year. The vaccine-known as MenAfriVac and specifically targeted for use in lowincome countries in Africa-was designed to be made available to governments at a price of fifty cents per dose. The Meningitis Vaccine Project is an example of how product development partnerships have reinvigorated research on vaccines for neglected diseases. These partnerships disperse the multiple tasks of product development across a network of partners that are best suited for each task. The vaccine was rapidly embraced by African health officials, and in its first few weeks on the market, in late 2010, more than nineteen million people in Burkina Faso, Mali, and Niger were vaccinated.

AB - The Meningitis Vaccine Project, a so-called product development partnership, developed a new vaccine against bacterial meningitis, an inflammation of brain tissues that causes an estimated 10,000 deaths among African children and young people each year. The vaccine-known as MenAfriVac and specifically targeted for use in lowincome countries in Africa-was designed to be made available to governments at a price of fifty cents per dose. The Meningitis Vaccine Project is an example of how product development partnerships have reinvigorated research on vaccines for neglected diseases. These partnerships disperse the multiple tasks of product development across a network of partners that are best suited for each task. The vaccine was rapidly embraced by African health officials, and in its first few weeks on the market, in late 2010, more than nineteen million people in Burkina Faso, Mali, and Niger were vaccinated.

UR - http://www.scopus.com/inward/record.url?scp=79959497102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959497102&partnerID=8YFLogxK

U2 - 10.1377/hlthaff.2011.0295

DO - 10.1377/hlthaff.2011.0295

M3 - Article

C2 - 21653957

AN - SCOPUS:79959497102

VL - 30

SP - 1058

EP - 1064

JO - Health Affairs

JF - Health Affairs

SN - 0278-2715

IS - 6

ER -